Endo International (ENDP) Announces Favorable Final California Opioid Ruling
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St falls as oil ticks up, yields rise ahead of US-China summit
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil up almost 2% as Iran's president vows to never surrender
- On Holding sets 2029 financial targets, authorizes $1B share buyback
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Nasdaq reaches record high close, AI stocks rally
- Elmet Group signs tungsten offtake deal with Hemerdon Mine
- Meta bull case increasingly playing out, Mizuho says
Endo Announces Favorable Final Ruling in California State Court Opioid Trial
December 15, 2021 10:23 AM ESTDUBLIN, Dec. 15, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California trial court issuing a final ruling that the defendants, including Endo's wholly-owned subsidiaries Endo Health Solutions Inc. (EHSI) and Endo Pharmaceuticals Inc. (EPI), are not liable.
